阿可替尼

Tier A — Act now

Acalabrutinib · all drugs expiring in 2030 →

阿斯利康

Originator

2017

First approval

2030

Expiry (public)

$3.52B ▲

Peak sales

化学药

Type

Targets：BTK

Brand：Calquence、康可期

Indications (approved)：套细胞淋巴瘤、慢性淋巴细胞白血病、淋巴细胞性白血病

Regional status

批准上市

2017-10-31

批准上市

2020-11-05

China

批准上市

2023-03-21

Japan

批准上市

2021-01-22

Synthetic routes & intermediates2 routes

Originator routes × 1Optimised (non-patent) × 1Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield 10.5 mg

Code	CAS No.	Intermediate
ACAT-001	55557-52-3 Available	3-chloropyrazine-2-carbonitrile
ACAT-002	939412-86-9 Available	(3-chloropyrazin-2-yl)methanamine hydrochloride
ACAT-003	1148-11-4 Available	((benzyloxy)carbonyl)-L-proline
ACAT-004	1418307-17-1 Available	benzyl (S)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate
ACAT-005	1418307-18-2 Available	benzyl (S)-2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate
ACAT-006	1420478-87-0 Available	benzyl (S)-2-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate
ACAT-007	1420478-88-1 Available	benzyl (S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate
ACAT-008	850568-25-1 Available	N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
ACAT-009	1420478-89-2 Available	benzyl (S)-2-(8-amino-1-(4-(pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate
ACAT-010	1420478-90-5 Available	(S)-4-(8-amino-3-(pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
ACAT-011	590-93-2 Available	4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid

OptimisedRoute 2Steps 4 · Total yield 0.4 g (Acalabrutinib)

Synthetic routes & intermediates Route 2

Code	CAS No.	Intermediate
ACAT-012	586-76-5 Available	4-bromobenzoic acid
ACAT-013	504-29-0 Available	pyridin-2-amine
ACAT-014	121246-96-6 Available	(4-(pyridin-2-ylcarbamoyl)phenyl)boronic acid
ACAT-015	-	3-chloropyrazine-2-carbaldehyde
ACAT-016	-	4-(amino(3-chloropyrazin-2-yl)methyl)-N-(pyridin-2-yl)benzamide
ACAT-017	-	but-2-ynoyl-L-proline

Frequently asked questions

What are the approved indications of Acalabrutinib?

Approved indications include: 套细胞淋巴瘤, 慢性淋巴细胞白血病, 淋巴细胞性白血病.

When does the Acalabrutinib patent expire?

Based on public sources, the Acalabrutinib patent expires in 2030.

How many synthesis routes are recorded for Acalabrutinib?

2 synthesis routes are recorded; the shortest is 4 steps with 0.4 g (Acalabrutinib) total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Acalabrutinib intermediates?

14 intermediate CAS of Acalabrutinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Acalabrutinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-24